DoD Spinal Cord Injury, Clinical Trial Award | W81XWH 19 SCIRP CTA

Opportunity Information: Apply for W81XWH 19 SCIRP CTA

The Department of Defense Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA), funding opportunity number W81XWH 19 SCIRP CTA, is a discretionary research and development grant/cooperative agreement mechanism run through the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). Its core purpose is to accelerate the launch and execution of clinical trials in spinal cord injury (SCI) that could meaningfully change how SCI is treated or managed in real-world clinical settings. The emphasis is on speed to implementation and on trials that are positioned to produce clinically relevant evidence, rather than early exploratory laboratory work.

The opportunity is designed to support a broad range of SCI-focused clinical studies, including trials that test promising new products and interventions such as pharmacologic agents (both drugs and biologics), medical devices, clinical guidance or care approaches, and emerging technologies. In practice, this means applicants can propose studies that evaluate novel therapeutics, rehabilitation strategies, neuromodulation or assistive technologies, diagnostic or monitoring tools, or other interventions intended to improve outcomes for individuals living with SCI. The program framing makes it clear that the funder is looking for work with a plausible path to changing patient care, whether through improved function, reduced complications, better symptom control, or more effective clinical decision-making.

A notable feature of this CTA is the wide span of allowable trial maturity. Projects can be smaller, early-stage proof-of-concept efforts, including pilot studies, first-in-human work, or Phase 0 trials, when the goal is to show feasibility, demonstrate safety signals, refine protocols, or generate the data needed to justify and properly design a larger pivotal study. At the same time, the mechanism can support larger-scale trials aimed at determining efficacy in appropriate patient populations, suggesting the program is open to well-developed trials that are ready to answer definitive clinical questions. This flexibility allows investigators and institutions to align their proposal with the current readiness of their intervention while still fitting within a clinical trial framework.

Eligibility is listed as unrestricted, meaning the competition is broadly open to any type of applicant organization, subject to any additional clarifications that may be provided in the full announcement. The funding activity category is Science and Technology and other Research and Development, with CFDA number 12.420. The funding instruments available are grants and cooperative agreements, which generally indicates that some awards may involve a closer working relationship with the government compared with a standard grant, depending on the project and award structure.

Administratively, the opportunity was created on April 15, 2019, with an original closing date of August 27, 2019, and it anticipated making about three awards. The published award ceiling is listed as 0, which typically signals that a maximum dollar amount was not stated in the summary field and would need to be confirmed in the full funding announcement and associated program guidelines. Overall, the CTA is positioned as a mechanism for moving SCI interventions into clinical testing quickly, supporting trials that range from early feasibility work to larger efficacy studies, with the overarching aim of producing evidence that can significantly improve treatment or management of spinal cord injury.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Spinal Cord Injury, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 15, 2019.
• Applicants must submit their applications by Aug 27, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 SCIRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: